Marker associated with non-alcoholic steatohepatitis
AssigneeMochida Pharmaceutical Co., Ltd.
InventorsAyumi Sato, Tsuyoshi Harada, Takashi Yano, Yoko Wakabayashi
Life of this patent
Estimating the term…
Abstract
Disclosed is a novel NASH marker for use in a method for detecting NASH or evaluating the severity of NASH, which utilizes at least one factor selected from the group consisting of an IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA and an sPLA2 activity as the marker. Also disclosed is a method for detecting NASH or evaluating the severity of NASH in a subject, which utilizes the marker.
Claims6
A method for detecting non-alcoholic steatohepatitis or evaluating seriousness thereof comprising the step of measuring at least one factor selected from the group consisting of IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA, and sPLA2 activity in a biological specimen from a subject as a marker.
An assay kit for detection of non-alcoholic steatohepatitis or evaluation of seriousness thereof or therapeutic effects thereon comprising an antibody or a fragment thereof against at least one member selected from the group consisting of IL-1 receptor antagonist, sCD40, HMGB1, sPLA2 group IIA, IL-2, apolipoprotein A-IV, apolipoprotein C-II, CCL2, thrombospondin 1, trehalase, MMP12, MMP13, TIMP1, complement factor D, lipoprotein lipase, alpha chain of IL-3 receptor, locus D of lymphocyte antigen 6 complex, COL1a1, member 19 of TNFR superfamily (TAJ), TNFAIP6, VLDLR, members 1, 2, 3, and 12 of EarA family, INSL5, TGF β2, HAMP, lipase H, and CYP7B1, and/or a substrate for measuring sPLA2 activity.
Dependencies are inferred from the claim text.